SCHEMBL28657459

SCHEMBL28657459

Cc1ccc(S(=O)(=O)O)cc1OCCCO

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 1/20 0.47
TSHR P16473 3/20 0.45
PPARA Q07869 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TTR P02766 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C8 P10632 1/20 0.40
CHRM1 P11229 1/20 0.40
CYP2C9 P11712 1/20 0.40
ADRA1A P35348 1/20 0.40
PPARG P37231 1/20 0.40
HTR2B P41595 1/20 0.40
SLCO1B3 Q9NPD5 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CISD1 Q9NZ45 1/20 0.40
SLCO1B1 Q9Y6L6 1/20 0.40
ALDH1A1 P00352 3/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
HTT P42858 2/20 0.40
KDM4E B2RXH2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29236336 0.87 S1PR3 (0.41) S1PR3TSHRPPARASMN1; SMN2TTR
SCHEMBL14542266 0.85 S1PR3 (0.65) S1PR3TSHRHTR2BALDH1A1HTT
SCHEMBL14541876 0.85 S1PR3 (0.65) S1PR3TSHRHTR2BALDH1A1HTT
SCHEMBL9219685 0.85 S1PR3 (0.65) S1PR3TSHRHTR2BALDH1A1HTT
SCHEMBL14528304 0.85 S1PR3 (0.65) S1PR3TSHRHTR2BALDH1A1HTT
SCHEMBL30184755 0.82 HTT (0.46) S1PR3TSHRSMN1; SMN2TDP1ALDH1A1
SCHEMBL1778964 0.82 KDM4E (0.46) S1PR3TSHRSMN1; SMN2CYP1A2ADRA1A
SCHEMBL564008 0.81 S1PR3 (0.41) S1PR3TSHRPPARASMN1; SMN2TTR
SCHEMBL14915169 0.81 S1PR3 (0.41) S1PR3TSHRPPARASMN1; SMN2TTR
SCHEMBL9935430 0.81 S1PR3 (0.41) S1PR3TSHRPPARASMN1; SMN2TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113423427-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2021-09-21 CN disclosed